PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 1360533-2 1992 5-Aminosalicylic acid (25-100 micrograms mL-1) inhibited PAF release by ricinoleic acid in a concentration-dependent manner, and 50 micrograms mL-1 reduced the effect of A23187. Mesalamine 0-21 PCNA clamp associated factor Homo sapiens 57-60 1360533-0 1992 PAF formation by human gastrointestinal mucosa/submucosa in-vitro: release by ricinoleic acid, and inhibition by 5-aminosalicylic acid. Mesalamine 113-134 PCNA clamp associated factor Homo sapiens 0-3 1359744-5 1992 The enhanced stimulation of PAF induced by A23187 was dose-dependently inhibited by sulphasalazine, 5-aminosalicylic acid and prednisolone, but not by sulfapyridine. Mesalamine 100-121 PCNA clamp associated factor Homo sapiens 28-31 1794301-0 1991 Release of platelet-activating factor (PAF) from human colon mucosa and its inhibition by 5-aminosalicylic acid. Mesalamine 90-111 PCNA clamp associated factor Homo sapiens 11-37 1794301-0 1991 Release of platelet-activating factor (PAF) from human colon mucosa and its inhibition by 5-aminosalicylic acid. Mesalamine 90-111 PCNA clamp associated factor Homo sapiens 39-42 1794301-4 1991 5-ASA 25-100 micrograms/ml caused a 5-100% inhibition of the PAF release by 50 micrograms/ml ricinoleic acid. Mesalamine 0-5 PCNA clamp associated factor Homo sapiens 61-64 1794301-5 1991 The authors conclude that PAF can be released by damage to human colonic mucosa/submucosa, and that the inhibition of PAF release in ulcerative colitis may at least partly explain the therapeutic effect of 5-ASA. Mesalamine 206-211 PCNA clamp associated factor Homo sapiens 26-29 1794301-5 1991 The authors conclude that PAF can be released by damage to human colonic mucosa/submucosa, and that the inhibition of PAF release in ulcerative colitis may at least partly explain the therapeutic effect of 5-ASA. Mesalamine 206-211 PCNA clamp associated factor Homo sapiens 118-121